Abstract
Cell therapy is poised to play a larger role in medicine, most notably for immuno-oncology. Despite the recent success of CAR-T therapeutics in the treatment of blood tumors and the rapid progress toward improved versions of both CAR- and TCR-Ts, important analytical aspects of preclinical development and manufacturing of engineered T cells remain immature. One limiting factor is the absence of robust multivariate assays to disentangle key parameters related to function of engineered effector cells, especially in the peptide-MHC (pMHC) target realm, the natural ligand for TCRs. Here we describe an imaging-based primary T cell assay that addresses several of these limitations. To our knowledge, this assay is the first quantitative, high-content assay that separates the key functional parameters of time- and antigen-dependent T cell proliferation from cytotoxicity. We show that the assay sheds light on relevant biology of CAR- and TCR-T cells, including response kinetics and the influence of effector:target ratio.
Publisher
Public Library of Science (PLoS)
Reference27 articles.
1. A guide to manufacturing CAR T cell therapies;P Vormittag;Curr Opin Biotechnol,2018
2. Designing chimeric antigen receptors to effectively and safely target tumors;MC Jensen;Curr Opin Immunol,2015
3. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma;FL Locke;Mol Ther,2017
4. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma;SJ Schuster;N Engl J Med,2019
5. Management of ‘out of specification’ commercial autologous CAR-T cell products;A Bersenev;Cell Gene Ther Insights,2018
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献